These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36355529)

  • 1. Data-Driven Technology Roadmaps to Identify Potential Technology Opportunities for Hyperuricemia Drugs.
    Feng L; Zhao W; Wang J; Lin KY; Guo Y; Zhang L
    Pharmaceuticals (Basel); 2022 Nov; 15(11):. PubMed ID: 36355529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Untargeted metabolomics reveal the therapeutic effects of Ermiao wan categorized formulas on rats with hyperuricemia.
    Shan B; Chen T; Huang B; Liu Y; Chen J
    J Ethnopharmacol; 2021 Dec; 281():114545. PubMed ID: 34419610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An integrated study of Shenling Baizhu San against hyperuricemia: Efficacy evaluation, core target identification and active component discovery.
    Wang Y; Lin ZJ; Huang J; Chu MZ; Ding XL; Li WJ; Mao QY; Zhang B
    J Ethnopharmacol; 2022 Sep; 295():115450. PubMed ID: 35688256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DKB114, A Mixture of
    Lee YS; Kim SH; Yuk HJ; Kim DS
    Nutrients; 2018 Sep; 10(10):. PubMed ID: 30274153
    [No Abstract]   [Full Text] [Related]  

  • 5. Triterpenoid acids from medicinal mushroom Inonotus obliquus (Chaga) alleviate hyperuricemia and inflammation in hyperuricemic mice: Possible inhibitory effects on xanthine oxidase activity.
    Luo LS; Wang Y; Dai LJ; He FX; Zhang JL; Zhou Q
    J Food Biochem; 2022 Mar; 46(3):e13932. PubMed ID: 34528276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innovation technology opportunity identification of civil aircraft mechanical connections based on generative topographic mapping.
    Feng L; Zhang H; Wang J; Lin KY; Li J
    PLoS One; 2023; 18(10):e0293309. PubMed ID: 37862326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipidomics to investigate the pharmacologic mechanisms of ginkgo folium in the hyperuricemic rat model.
    Zhang S; Zhuang J; Yue G; Wang Y; Liu M; Zhang B; Du Z; Ma Q
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Aug; 1060():407-415. PubMed ID: 28672255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database.
    Ito S; Torii T; Nakajima A; Iijima T; Murano H; Horiuchi H; Yamanaka H; Honda M
    BMC Pediatr; 2020 Oct; 20(1):481. PubMed ID: 33059648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a traditional Chinese medicine prescription Quzhuotongbi decoction on hyperuricemia model rats studied by using serum metabolomics based on gas chromatography-mass spectrometry.
    Chen J; Zhou J; Wei S; Xie Z; Wen C; Xu G
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jul; 1026():272-278. PubMed ID: 26632444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Technological opportunity discovery for technological convergence based on the prediction of technology knowledge flow in a citation network.
    Park I; Yoon B
    J Informetr; 2018 Nov; 12(4):1199-1222. PubMed ID: 32336982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of hyperuricemia with rasburicase review.
    de Bont JM; Pieters R
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1431-40. PubMed ID: 15571272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a potent inhibitor of xanthine oxidase: a potential therapeutic agent for treatment of hyperuricemia and gout.
    Lü JM; Yao Q; Chen C
    Biochem Pharmacol; 2013 Nov; 86(9):1328-37. PubMed ID: 23994369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of uric acid to cancer risk, recurrence, and mortality.
    Fini MA; Elias A; Johnson RJ; Wright RM
    Clin Transl Med; 2012 Aug; 1(1):16. PubMed ID: 23369448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of the metabolic syndrome in individuals with hyperuricemia.
    Choi HK; Ford ES
    Am J Med; 2007 May; 120(5):442-7. PubMed ID: 17466656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure.
    Borghi C; Palazzuoli A; Landolfo M; Cosentino E
    Heart Fail Rev; 2020 Jan; 25(1):43-51. PubMed ID: 31745840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineered
    Zhao R; Li Z; Sun Y; Ge W; Wang M; Liu H; Xun L; Xia Y
    Gut Microbes; 2022; 14(1):2070391. PubMed ID: 35491895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction and expression of recombinant uricase‑expressing genetically engineered bacteria and its application in rat model of hyperuricemia.
    Cai L; Li Q; Deng Y; Liu X; Du W; Jiang X
    Int J Mol Med; 2020 May; 45(5):1488-1500. PubMed ID: 32323736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel xanthine oxidase-based cell model using HK-2 cell for screening antihyperuricemic functional compounds.
    Hou C; Liu D; Wang M; Gong C; Li Y; Yang L; Yao M; Yuan E; Ren J
    Free Radic Biol Med; 2019 May; 136():135-145. PubMed ID: 30980888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uric acid and transplantation.
    Mazali FC; Mazzali M
    Semin Nephrol; 2011 Sep; 31(5):466-71. PubMed ID: 22000655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia.
    Bove M; Cicero AF; Veronesi M; Borghi C
    Vasc Health Risk Manag; 2017; 13():23-28. PubMed ID: 28223818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.